Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The T cell receptor (TCR) recognizing Quercus nigra (Water Oak) pollen-derived peptides presented by MHC is a critical mediator of allergic sensitization and symptomatic disease (PubMed: 31254321). This TCR complex, typically found on CD4+ T helper cells, specifically binds to allergenic peptides, such as those from the major allergen Que n 1, when they are displayed by Major Histocompatibility Complex (MHC) Class II molecules on antigen-presenting cells (UniProt: P80847). Upon binding, the TCR triggers a signaling cascade that leads to the activation and proliferation of Th2 cells, which drive the production of allergen-specific IgE and the recruitment of inflammatory cells like eosinophils and mast cells (StatPearls: Type I Hypersensitivity). In the context of disease, this interaction is responsible for the inflammatory response seen in allergic rhinitis and allergic asthma during the oak pollination season (NIH: Pollen Allergies). Therapeutic strategies targeting this TCR interaction primarily involve allergen-specific immunotherapy (AIT), which aims to induce immune tolerance by shifting the T cell response from a pro-inflammatory Th2 profile to a regulatory or Th1-weighted profile (PubMed: 28214150). Monitoring the activity and frequency of these specific T cell populations is essential for evaluating the efficacy of desensitization treatments. Safety concerns for therapies hitting this target include the risk of systemic allergic reactions or anaphylaxis during the administration of the allergen.
Allergen-specific immunotherapy (AIT) targets this TCR-MHC interaction by providing controlled exposure to the allergen, which induces T cell anergy, deletion, or a shift toward a regulatory T cell (Treg) phenotype, thereby reducing the Th2-driven allergic response (PubMed: 28214150).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor recognizing Quercus nigra pollen-derived peptides presented by MHC (TCR).